Related Experiment Video
Updated: Apr 11, 2026
09:09
Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
Published on: November 10, 2017
9.0K
Chronic lymphocytic leukemia and the Warburg effect
1HOSPITAL SANTA CREU I SANT PAU.
Blood
|May 30, 2015
Summary
Researchers found that chronic lymphocytic leukemia (CLL) cells undergo a metabolic shift, driven by Notch-c-Myc signaling. Targeting this pathway may help overcome drug resistance in CLL patients.
Area of Science:
- Oncology
- Cancer Metabolism
- Cell Signaling
Background:
- Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
- Drug resistance remains a significant challenge in CLL treatment.
- The tumor microenvironment plays a crucial role in cancer progression and drug resistance.
Purpose of the Study:
- To investigate the metabolic reprogramming in CLL cells within their microenvironment.
- To elucidate the role of Notch-c-Myc signaling in mediating metabolic changes in CLL.
- To explore potential therapeutic strategies targeting metabolic pathways in CLL.
Main Methods:
- Analysis of CLL cell metabolism in co-culture models simulating the tumor microenvironment.
- Investigation of Notch and c-Myc signaling pathway activation in CLL cells.
- Metabolic flux analysis to quantify glycolytic activity.
- Assessment of drug sensitivity following pathway modulation.
Main Results:
- Demonstrated a significant shift towards glycolysis in CLL cells within the microenvironment.
- Identified Notch-c-Myc signaling as a key mediator of this glycolytic reprogramming.
- Showcased that interfering with Notch-c-Myc signaling alters CLL cell metabolism.
- Observed potential implications for overcoming drug resistance.
Conclusions:
- Notch-c-Myc signaling drives a microenvironmental glycolytic shift in CLL cells.
- Reprogramming glycolytic metabolism presents a potential therapeutic avenue for CLL.
- Targeting the Notch-c-Myc pathway could be a strategy to enhance treatment efficacy in CLL.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
7.5K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.5K
01:27Disorders of Leukocytes
2.5K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.5K
02:23Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
03:03mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K
01:22PI3K/mTOR/AKT Signaling Pathway
6.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.4K